Latest Regulatory Reviews News

PMET Resources posted a CAD 2.1 million net loss for Q1 2026, bolstered by strategic partnerships and a strong cash position as it pushes forward with its flagship Shaakichiuwaanaan lithium project.

Jindalee Lithium has taken another regulatory step by filing an amended Form S-4 with the US SEC, progressing its plan to spin out US lithium assets via US Elemental and list on NASDAQ.

Commonwealth Bank of Australia delivered a solid FY26 with 7% growth in net profit and a strong capital position, while continuing investments in AI and customer protection.

AMP Limited reported a robust first half of 2026, with statutory profit rising 57% to $154 million and underlying profit up 33%, driven by strong Platforms growth, positive cashflows, and a doubling of China partnership contributions.

Cygnus Metals has lodged its draft scheme booklet with ASIC, moving closer to a planned acquisition by Central Asia Metals. Regulatory approvals in North Macedonia are complete, with Kazakhstan clearance still pending.

Clarity Pharmaceuticals bolsters its commercial readiness with a $178.3 million cash reserve and a key US manufacturing agreement, while clinical trials for its prostate cancer imaging and therapeutic agents progress with promising data.

Finder Energy has secured key regulatory approval for its KTJ Project in Timor-Leste and raised $27 million to advance development, positioning for a Final Investment Decision in Q3 2026.

Echo IQ has locked in a strategic $20 million investment and US partnership with Pro Medicus, alongside a $110 million capital raise, positioning the company for accelerated commercial expansion of its AI-driven cardiovascular diagnostics in the US.

Amaero Inc. capped FY2026 with a record A$18.1 million revenue, expanded its production capacity, and landed a A$6.5 million US Department of War contract to develop alternative refractory alloy powders.

Paladin Energy completes Langer Heinrich Mine ramp-up, delivering strong FY2026 results and advancing its Canadian PLS Project with a new uranium discovery. FY2027 guidance forecasts stable production and costs amid ongoing regulatory progress.

The Takeovers Panel has received an application alleging undisclosed associations and possible breaches of takeover laws following a massive off-market transfer of Adslot shares valued at $723,870.

PYC Therapeutics reports durable retinal gene expression and visual improvements from its PYC-001 candidate in Autosomal Dominant Optic Atrophy, supporting longer dosing intervals and expansion into glaucoma research.